Benzodiazepine use and risk of Alzheimer's disease: Case-control study

BMJ (Online)

Volumn 349, Issue , 2014, Pages

  De Gage, Sophie Billioti ^a   Moride, Yola ^b,c   Ducruet, Thierry ^b   Kurth, Tobias ^a,d   Verdoux, Hélène ^a,e   Tournier, Marie ^a,e   Pariente, Antoine ^a   Bégaud, Bernard ^a  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

^d INSERM   (France)

^e CENTRE HOSPITALIER CHARLES PERRENS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; BENZODIAZEPINE DERIVATIVE; BROMAZEPAM; CHLORDIAZEPOXIDE; CLOBAZAM; CLONAZEPAM; DIAZEPAM; FLURAZEPAM; LORAZEPAM; MIDAZOLAM; NITRAZEPAM; OXAZEPAM; TEMAZEPAM; TRIAZOLAM;

AGED; ALZHEIMER DISEASE; ANXIETY DISORDER; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; DRUG EXPOSURE; ELIMINATION HALF-LIFE; FEMALE; HIGH RISK PATIENT; HUMAN; INSOMNIA; LONG TERM EXPOSURE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUEBEC; RISK FACTOR; TREATMENT DURATION; VERY ELDERLY;

EID: 84988826680     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.g5205     Document Type: Article

References (65)

1. World Alzheimer Report 2009. Alzheimer Disease International, 2009.
2. Dementia: a public health priority. World Health Organization, 2012.
3. Leicht H, Heinrich S, Heider D, Bachmann C, Bickel H, van den Bussche H, et al. Net costs of dementia by disease stage. Acta Psychiatr Scand 2011;124:384-95.
4. Fineberg NA, Haddad PM, Carpenter L, Gannon B, Sharpe R, Young AH, et al. The size, burden and cost of disorders of the brain in the UK. J Psychopharmacol 2013;27:761-70.
5. Wu CS, Wang SC, Chang IS, Lin KM. The association between dementia and long-term use of benzodiazepine in the elderly: nested case-control study using claims data. Am J Geriatr Psychiatry 2009;17:614-20.
6. Wu CS, Ting TT, Wang SC, Chang IS, Lin KM. Effect of benzodiazepine discontinuation on dementia risk. Am J Geriatr Psychiatry 2011;19:151-9.
7. Lagnaoui R, Begaud B, Moore N, Chaslerie A, Fourrier A, Letenneur L, et al. Benzodiazepine use and risk of dementia: a nested case-control study. J Clin Epidemiol 2002;55:314-8.
8. Gallacher J, Elwood P, Pickering J, Bayer A, Fish M, Ben-Shlomo Y. Benzodiazepine use and risk of dementia: evidence from the Caerphilly Prospective Study (CaPS). J Epidemiol Community Health 2012;66:869-73.
9. Billioti de Gage S, Begaud B, Bazin F, Verdoux H, Dartigues JF, Peres K, et al. Benzodiazepine use and risk of dementia: prospective population based study. BMJ 2012;345:e6231.
10. European Medicines Agency. Summary of product characteristics for benzodiazepines as anxiolytics or hypnotics. EMA, 1994.
11. Donoghue J, Lader M. Usage of benzodiazepines. A review. Int J Psychiatry in Clin Pract 2010;14:78-87.
12. Dell'osso B, Lader M. Do benzodiazepines still deserve a major role in the treatment of psychiatric disorders? A critical reappraisal. Eur Psychiatry 2013;28:7-20.
13. Cheng JS, Huang WF, Lin KM, Shih YT. Characteristics associated with benzodiazepine usage in elderly outpatients in Taiwan. Int J Geriatr Psychiatry 2008;23:618-24.
14. Paulose-Ram R, Safran MA, Jonas BS, Gu Q, Orwig D. Trends in psychotropic medication use among U. S.adults. Pharmacoepidemiol Drug Saf 2007;16:560-70.
15. Vinkers CH, Olivier B. Mechanisms underlying tolerance after long-term benzodiazepine use: a future for subtype-selective GABA (A) receptor modulators? Adv Pharmacol Sci 2012;2012:416864.
16. Poyares D, Guilleminault C, Ohayon MM, Tufik S. Chronic benzodiazepine usage and withdrawal in insomnia patients. J Psychiatr Res 2004;38:327-34.
17. Monane M, Glynn RJ, Avorn J. The impact of sedative-hypnotic use on sleep symptoms in elderly nursing home residents. Clin Pharmacol Ther 1996;59:83-92.
18. Curran HV, Collins R, Fletcher S, Kee SC, Woods B, Iliffe S. Older adults and withdrawal from benzodiazepine hypnotics in general practice: effects on cognitive function, sleep, mood and quality of life. Psychol Med 2003;33:1223-37.
19. Neutel CI. The epidemiology of long-term benzodiazepine use. Int Rev Psychiatry 2005;17:189-97.
20. Egan M, Moride Y, Wolfson C, Monette J. Long-term continuous use of benzodiazepines by older adults in Quebec: prevalence, incidence and risk factors. J Am Geriatr Soc 2000;48:811-6.
21. Lister RG. The amnesic action of benzodiazepines in man. Neurosci Biobehav Rev 1985;9:87-94.
22. Ghoneim MM, Mewaldt SP. Benzodiazepines and human memory: a review. Anesthesiology 1990;72:926-38.
23. Curran HV. Tranquillising memories: a review of the effects of benzodiazepines on human memory. Biol Psychol 1986;23:179-213.
24. Buffett-Jerrott SE, Stewart SH. Cognitive and sedative effects of benzodiazepine use. Curr Pharm Des 2002;8:45-58.
25. Taragano FE, Allegri RF, Krupitzki H, Sarasola DR, Serrano CM, Lon L, et al. Mild behavioral impairment and risk of dementia: a prospective cohort study of 358 patients. J Clin Psychiatry 2009;70:584-92.
26. Rosenberg PB, Mielke MM, Appleby B, Oh E, Leoutsakos JM, Lyketsos CG. Neuropsychiatric symptoms in MCI subtypes: the importance of executive dysfunction. Int J Geriatr Psychiatry 2011;26:364-72.
27. Lyketsos CG, Lopez O, Jones B, Fitzpatrick AL, Breitner J, DeKosky S. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. JAMA 2002;288:1475-83.
28. Amieva H, Le Goff M, Millet X, Orgogozo JM, Peres K, Barberger-Gateau P, et al. Prodromal Alzheimer's disease: successive emergence of the clinical symptoms. Ann Neurol 2008;64:492-8.
29. Introduction to drug utilization research. World Health Organization, 2003.
30. Li J, Wang YJ, Zhang M, Xu ZQ, Gao CY, Fang CQ, et al. Vascular risk factors promote conversion from mild cognitive impairment to Alzheimer disease. Neurology 2011;76:1485-91.
31. Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E. Alzheimer's disease. Lancet 2011;377:1019-31.
32. Lechevallier N, Fourrier A, Berr C. [Benzodiazepine use in the elderly: the EVA Study]. Rev Epidemiol Sante Publique 2003;51:317-26.
33. Fourrier A, Letenneur L, Dartigues JF, Moore N, Begaud B. Benzodiazepine use in an elderly community-dwelling population. Characteristics of users and factors associated with subsequent use. Eur J Clin Pharmacol 2001;57:419-25.
34. Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005;43:1130-9.
35. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-9.
36. Ownby RL, Crocco E, Acevedo A, John V, Loewenstein D. Depression and risk for Alzheimer disease: systematic review, meta-analysis, and metaregression analysis. Arch Gen Psychiatry 2006;63:530-8.
37. Dotson VM, Beydoun MA, Zonderman AB. Recurrent depressive symptoms and the incidence of dementia and mild cognitive impairment. Neurology 2010;75:27-34.
38. Byers AL, Yaffe K. Depression and risk of developing dementia. Nat Rev Neurol 2011;7:323-31.
39. Van der Mussele S, Le Bastard N, Vermeiren Y, Saerens J, Somers N, Marien P, et al. Behavioral symptoms in mild cognitive impairmentas compared with Alzheimer's disease and healthy older adults. Int J Geriatr Psychiatry 2013;28:265-75.
40. Johansson L, Guo X, Waern M, Ostling S, Gustafson D, Bengtsson C, et al. Midlife psychological stress and risk of dementia: a 35-year longitudinal population study. Brain 2010;133:2217-24.
41. Sterniczuk R, Theou O, Rusak B, Rockwood K. Sleep disturbance is associated with incident dementia and mortality. Curr Alzheimer Res 2013;10:767-75.
42. Kang JE, Lim MM, Bateman RJ, Lee JJ, Smyth LP, Cirrito JR, et al. Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle. Science 2009;326:1005-7.
43. Ju YE, Lucey BP, Holtzman DM. Sleep and Alzheimer disease pathology-a bidirectional relationship. Nat Rev Neurol 2014;10:115-9.
44. Assem-Hilger E, Jungwirth S, Weissgram S, Kirchmeyr W, Fischer P, Barnas C. Benzodiazepine use in the elderly: an indicator for inappropriately treated geriatric depression? Int J Geriatr Psychiatry 2009;24:563-9.
45. Lagnaoui R, Tournier M, Moride Y, Wolfson C, Ducruet T, Begaud B, et al. The risk of cognitive impairment in older community-dwelling women after benzodiazepine use. Age Ageing 2009;38:226-8.
46. Fastbom J, Forsell Y, Winblad B. Benzodiazepines may have protective effects against Alzheimer disease. Alzheimer Dis Assoc Dis 1998;12:14-7.
47. Swaen G, van Amelsvoort L. A weight of evidence approach to causal inference. J Clin Epidemiol 2009;62:270-7.
48. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98.
49. Ostbye T, Kristjansson B, Hill G, Newman SC, Brouwer RN, McDowell I. Prevalence and predictors of depression in elderly Canadians: the Canadian Study of Health and Aging. Chronic Dis Can 2005;26:93-9.
50. Beekman AT, Bremmer MA, Deeg DJ, van Balkom AJ, Smit JH, de Beurs E, et al. Anxiety disorders in later life: a report from the Longitudinal Aging Study Amsterdam. Int J Geriatr Psychiatry 1998;13:717-26.
51. Lemeshow S, Letenneur L, Dartigues JF, Lafont S, Orgogozo JM, Commenges D. Illustration of analysis taking into account complex survey considerations: the association between wine consumption and dementia in the PAQUID study. Personnes Ages Quid. Am J Epidemiol 1998;148:298-306.
52. Ilomaki J, Bell JS, Kauhanen J, Enlund H. Heavy drinking and use of sedative or anxiolytic drugs among aging men: an 11-year follow-up of the FinDrink study. Ann Pharmacother 2011;45:1240-7.
53. Valenzuela MJ, Sachdev P. Brain reserve and dementia: a systematic review. Psychol Med 2006;36:441-54.
54. Stern Y, Gurland B, Tatemichi TK, Tang MX, Wilder D, Mayeux R. Influence of education and occupation on the incidence of Alzheimer's disease. JAMA 1994;271:1004-10.
55. Aparasu RR, Mort JR, Brandt H. Psychotropic prescription use by community-dwelling elderly in the United States. J Am Geriatr Soc 2003;51:671-7.
56. Zandstra SM, Van Rijswijk E, Rijnders CA, Van De Lisdonk EH, Bor JH, Van Weel C, et al. Long-term benzodiazepine users in family practice: differences from short-term users in mental health, coping behaviour and psychological characteristics. Fam Pract 2004;21:266-9.
57. Veronese A, Garatti M, Cipriani A, Barbui C. Benzodiazepine use in the real world of psychiatric practice: low-dose, long-term drug taking and low rates of treatment discontinuation. Eur J Clin Pharmacol 2007;63:867-73.
58. Espana J, Gimenez-Llort L, Valero J, Minano A, Rabano A, Rodriguez-Alvarez J, et al. Intraneuronal beta-amyloid accumulation in the amygdala enhances fear and anxiety in Alzheimer's disease transgenic mice. Biol Psychiatry 2010;67:513-21.
59. Tannenbaum C, Paquette A, Hilmer S, Holroyd-Leduc J, Carnahan R. A systematic review of amnestic and non-amnestic mild cognitive impairment induced by anticholinergic, antihistamine, GABAergic and opioid drugs. Drugs Aging 2012;29:639-58.
60. Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, et al. Current concepts in mild cognitive impairment. Arch Neurol 2001;58:1985-92.
61. Busse A, Hensel A, Guhne U, Angermeyer MC, Riedel-Heller SG. Mild cognitive impairment: long-term course of four clinical subtypes. Neurology 2006;67:2176-85.
62. Hutchinson MA, Smith PF, Darlington CL. The behavioural and neuronal effects of the chronic administration of benzodiazepine anxiolytic and hypnotic drugs. Prog Neurobiol 1996;49:73-97.
63. Shimohama S, Taniguchi T, Fujiwara M, Kameyama M. Changes in benzodiazepine receptors in Alzheimer-type dementia. Ann Neurol 1988;23:404-6.
64. Stern Y. What is cognitive reserve? Theory and research application of the reserve concept. J Int Neuropsychol Soc 2002;8:448-60.
65. Pariente A, Dartigues JF, Benichou J, Letenneur L, Moore N, Fourrier-Reglat A. Benzodiazepines and injurious falls in community dwelling elders. Drugs Aging 2008;25:61-70.